NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products, today announced that it has signed two new distribution agreements to market its products in international markets.
Sarmedic Ltd will have exclusive rights to market and distribute NovaBay’s innovative eye care product Avenova™ in Israel. Alpha Pharma LLC will have exclusive rights to market and distribute NovaBay’s wound cleanser NeutroPhase® in the Ukraine.
“We are making headway with our strategy to engage distributors to market our products around the world,” said Ron Najafi, Ph.D., Chairman and CEO of NovaBay. “It is gratifying that quality distributors such as these find Avenova and NeutroPhase as valuable additions to their own product portfolios.”
NovaBay’s Avenova, NeutroPhase and CelleRx™ are the only products to contain Neutrox™, NovaBay’s proprietary pure hypochlorous acid (HOCl). Laboratory tests show that Neutrox, which emulates the naturally occurring substance released by white blood cells to fight microbial invaders, has potent antimicrobial activity in solution, and yet is non-toxic to healthy mammalian cells. It also neutralizes bacterial toxins in solution.
As a result of these properties and its cleansing function, Avenova is useful in the control of microorganism populations on the eyelids and lashes of patients suffering from such common chronic eye conditions as blepharitis and dry eye syndrome. The same properties have made NeutroPhase a valuable addition to the treatment paradigm used for the deadly ‘flesh-eating’ disease and for the care of chronic wounds.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a biopharmaceutical company focusing commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX™ Family of Products, including AVENOVA™ for the eye care market and NEUTROPHASE® for wound care, which was initially cleared by FDA, and CELLERX™ for the dermatology market; and its AGANOCIDE® compounds, led by AURICLOSENE™.
NovaBay is partnered in the U.S. and around the globe with: PBE, Inc. (USA), IHT, Inc. (USA), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (Korea), Biopharm (North African and Middle East), Sarmedic Ltd (Israel) and Alpha Pharma LLC (Ukraine).
This news release contains “forward-looking statements.” These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, commercial potential and financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” NovaBay undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
For NovaBay NeutroPhase purchasing information, please contact:
Contact a NeutroPhase Distributor
For investor information, please contact:
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson